Leuko
Leuko Labs is a venture-backed company spun out from MIT, developing PointCheck™, the first non-invasive white blood cell monitoring device designed for at-home use. The device uses light to image blood cells through the skin of the finger, enabling frequent, portable, and simple monitoring of white cell levels without blood draws. This technology targets immunosuppressed patients, especially chemotherapy patients at risk of severe neutropenia, to improve quality of life and clinical outcomes by early detection of dangerously low white cell levels and infection risk. The company has received multiple awards and grants, including SBIR from the National Cancer Institute, and is led by a team with expertise in medical devices, AI, and clinical validation. Leuko Labs aims to transform white blood cell testing by making it accessible, non-invasive, and convenient, addressing a significant unmet medical need in cancer care and infection prevention.
Leuko
Leuko Labs is a venture-backed company spun out from MIT, developing PointCheck™, the first non-invasive white blood cell monitoring device designed for at-home use. The device uses light to image blood cells through the skin of the finger, enabling frequent, portable, and simple monitoring of white cell levels without blood draws. This technology targets immunosuppressed patients, especially chemotherapy patients at risk of severe neutropenia, to improve quality of life and clinical outcomes by early detection of dangerously low white cell levels and infection risk. The company has received multiple awards and grants, including SBIR from the National Cancer Institute, and is led by a team with expertise in medical devices, AI, and clinical validation. Leuko Labs aims to transform white blood cell testing by making it accessible, non-invasive, and convenient, addressing a significant unmet medical need in cancer care and infection prevention.